EP1438325A2 - Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods - Google Patents
Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methodsInfo
- Publication number
- EP1438325A2 EP1438325A2 EP02763731A EP02763731A EP1438325A2 EP 1438325 A2 EP1438325 A2 EP 1438325A2 EP 02763731 A EP02763731 A EP 02763731A EP 02763731 A EP02763731 A EP 02763731A EP 1438325 A2 EP1438325 A2 EP 1438325A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- rampl
- protein
- humanized
- human
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 124
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title claims abstract description 114
- 241001465754 Metazoa Species 0.000 title claims abstract description 100
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 81
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 title abstract description 13
- 238000003556 assay Methods 0.000 title description 23
- 239000002773 nucleotide Substances 0.000 claims abstract description 51
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 51
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 49
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 47
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 42
- 108090000623 proteins and genes Proteins 0.000 claims description 269
- 102000004169 proteins and genes Human genes 0.000 claims description 201
- 210000004027 cell Anatomy 0.000 claims description 122
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 claims description 101
- 108020004414 DNA Proteins 0.000 claims description 63
- 230000000694 effects Effects 0.000 claims description 46
- 239000012528 membrane Substances 0.000 claims description 43
- 239000013604 expression vector Substances 0.000 claims description 39
- 125000000539 amino acid group Chemical group 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 36
- 230000014509 gene expression Effects 0.000 claims description 36
- 238000002360 preparation method Methods 0.000 claims description 25
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 20
- 101000760563 Homo sapiens Calcitonin gene-related peptide type 1 receptor Proteins 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 14
- 238000011830 transgenic mouse model Methods 0.000 claims description 14
- 210000004602 germ cell Anatomy 0.000 claims description 11
- 210000001082 somatic cell Anatomy 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 claims 4
- 101710118454 Calcitonin gene-related peptide type 1 receptor Proteins 0.000 abstract description 66
- 102000056906 Calcitonin Receptor-Like Human genes 0.000 abstract description 64
- 150000001413 amino acids Chemical class 0.000 abstract description 60
- 102000005962 receptors Human genes 0.000 abstract description 55
- 108020003175 receptors Proteins 0.000 abstract description 55
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract description 26
- DNKYDHSONDSTNJ-XJVRLEFXSA-N chembl1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 abstract description 26
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract description 25
- 230000000144 pharmacologic effect Effects 0.000 abstract description 23
- 239000013598 vector Substances 0.000 abstract description 21
- 108010033494 Receptor Activity-Modifying Protein 1 Proteins 0.000 abstract description 9
- 230000004048 modification Effects 0.000 abstract description 9
- 238000012986 modification Methods 0.000 abstract description 9
- 102000007184 Receptor Activity-Modifying Protein 1 Human genes 0.000 abstract 4
- 235000018102 proteins Nutrition 0.000 description 169
- 235000001014 amino acid Nutrition 0.000 description 66
- 229940024606 amino acid Drugs 0.000 description 61
- 241000700159 Rattus Species 0.000 description 57
- 108020004635 Complementary DNA Proteins 0.000 description 48
- 241000699666 Mus <mouse, genus> Species 0.000 description 46
- 238000010804 cDNA synthesis Methods 0.000 description 44
- 239000002299 complementary DNA Substances 0.000 description 44
- 108020004705 Codon Proteins 0.000 description 37
- 125000003275 alpha amino acid group Chemical group 0.000 description 36
- 108700019146 Transgenes Proteins 0.000 description 32
- 239000005557 antagonist Substances 0.000 description 27
- 239000012634 fragment Substances 0.000 description 25
- 241000894007 species Species 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 17
- ITIXDWVDFFXNEG-JHOUSYSJSA-N olcegepant Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCN(CC1)C=1C=CN=CC=1)NC(=O)N1CCC(CC1)N1C(NC2=CC=CC=C2C1)=O)C1=CC(Br)=C(O)C(Br)=C1 ITIXDWVDFFXNEG-JHOUSYSJSA-N 0.000 description 16
- 230000004186 co-expression Effects 0.000 description 14
- 241001515942 marmosets Species 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 210000000349 chromosome Anatomy 0.000 description 13
- 229940125904 compound 1 Drugs 0.000 description 13
- 210000001671 embryonic stem cell Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 102000050254 human CALCRL Human genes 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 102000040430 polynucleotide Human genes 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 150000003384 small molecules Chemical class 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 208000019695 Migraine disease Diseases 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 241000238631 Hexapoda Species 0.000 description 9
- 102100030697 Receptor activity-modifying protein 1 Human genes 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000000520 microinjection Methods 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 210000004102 animal cell Anatomy 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 230000009137 competitive binding Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 206010027599 migraine Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 6
- 238000010357 RNA editing Methods 0.000 description 6
- 230000026279 RNA modification Effects 0.000 description 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000003278 mimic effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- 239000003155 DNA primer Substances 0.000 description 5
- 108010021466 Mutant Proteins Proteins 0.000 description 5
- 102000008300 Mutant Proteins Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 101000968287 Homo sapiens Denticleless protein homolog Proteins 0.000 description 4
- 101000609277 Homo sapiens Inactive serine protease PAMR1 Proteins 0.000 description 4
- 101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 description 4
- 101000788669 Homo sapiens Zinc finger MYM-type protein 2 Proteins 0.000 description 4
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 4
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 4
- 101001126150 Solanum lycopersicum Probable aquaporin PIP-type pTOM75 Proteins 0.000 description 4
- 102100025085 Zinc finger MYM-type protein 2 Human genes 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000006561 Cluster Headache Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091060211 Expressed sequence tag Proteins 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
- 208000033830 Hot Flashes Diseases 0.000 description 3
- 206010060800 Hot flush Diseases 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 3
- 206010027603 Migraine headaches Diseases 0.000 description 3
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 208000008548 Tension-Type Headache Diseases 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 208000018912 cluster headache syndrome Diseases 0.000 description 3
- 210000001840 diploid cell Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 102200070457 rs757888349 Human genes 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229940127597 CGRP antagonist Drugs 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 102100021243 G-protein coupled receptor 182 Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- -1 RNA Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000700161 Rattus rattus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 108010063640 adrenomedullin receptors Proteins 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000004671 cell-free system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000002980 germ line cell Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 210000004283 incisor Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000001273 protein sequence alignment Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000003653 radioligand binding assay Methods 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108010001789 Calcitonin Receptors Proteins 0.000 description 1
- 102100038520 Calcitonin receptor Human genes 0.000 description 1
- 241000288943 Callitrichinae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101100356230 Escherichia coli (strain K12) recT gene Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101000584590 Homo sapiens Receptor activity-modifying protein 2 Proteins 0.000 description 1
- 101000584593 Homo sapiens Receptor activity-modifying protein 3 Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010064300 Receptor Activity-Modifying Proteins Proteins 0.000 description 1
- 102000015146 Receptor Activity-Modifying Proteins Human genes 0.000 description 1
- 102100030696 Receptor activity-modifying protein 2 Human genes 0.000 description 1
- 102100030711 Receptor activity-modifying protein 3 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241001481696 Rhipicephalus sanguineus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000035929 gnawing Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002951 small molecule assay Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 150000003679 valine derivatives Chemical class 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Definitions
- the present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode a humanized version of a calcitonin gene-related peptide (CGRP) receptor, which comprises the G-protein coupled receptor calcitonin- receptor-like receptor (CRLR) and the receptor-activity-modifying protein 1 (RAMPl).
- CGRP calcitonin gene-related peptide
- CRLR G-protein coupled receptor calcitonin- receptor-like receptor
- RAMPl receptor-activity-modifying protein 1
- the present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding a humanized version of a CGRP receptor, substantially purified forms of associated humanized version of a CGRP receptor, recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which specifically modulated human CGRP receptor activity utilizing the humanized version of RAMPl in various assays.
- the present invention also relates to cells and non-human transgenic animals wherein the endogenous gene encoding RAMPl has been engineered to provide for a CGRP receptor pharmacological profile similar to the human CGRP receptor.
- the transgenic animals of the present invention will provide for a phenotype whereby their pharmacological profile in regard to modulators of the CGRP receptor will mimic the human form of the receptor, not the form of the CGRP receptor endogenous to the transgenic animal.
- the present invention also relates to methods of screening for CGRP modulators which comprises utilizing a humanized version of the CGRP receptor to selectively identify modulators of human CGRP.
- Such CGRP receptor modulators will potentially be useful in the treatment of various disorders, including but not limited to migraine headaches, pain indications, menopausal hot flashes, migraine prophylaxis, chronic tension type headache, cluster headache, neurogenic or chronic inflammation, gastrointestinal disorders, type 2 diabetes and cardiovascular disorders.
- Calcitonin gene-related protein is a 37-amino acid neuropeptide that is expressed in a variety of cell types in both the central and peripheral nervous systems. In many tissues, CGRP-containing fibers are closely associated with blood vessels. Among the various physiological functions reported for CGRP, the most pronounced is vasodilation. CGRP is the most powerful of the vasodilator transmitters and its vasoactive effects have been demonstrated in a variety of blood vessels, including those in the cerebral, coronary, and mesenteric vasculature.
- CGRP is involved in the pathophysiology of migraine headache.
- Migraine is thought to be associated with dilation of cerebral blood vessels and activation of the trigeminovascular system.
- CGRP levels are elevated in the cranial venous circulation.
- Successful amelioration of the headache results in normalization of CGRP levels, thus implicating CGRP in the pathophysiology of this disorder.
- intravenous administration of CGRP to migraineurs induces a delayed migrainous headache in some patients.
- McLatchie, et al. (1998, Nature 393: 333-339) disclose the gene encoding the human receptor-activity modifying proteins (hRAMPl).
- CGRP human receptor component protein
- hRCP human receptor component protein
- CRLR calcitonin receptor-like receptor
- RAMPl receptor activity modifying protein-1
- GPCR G s -coupled G-protein coupled receptor
- McLatchie et al. disclose that functional CGRP and adrenomedullin receptors are both derived from CRLR and that the phenotype is determined by co-expression with a particular RAMP. Co-expression of CRLR with RAMPl results in CGRP receptor pharmacology, while RAMP2 or RAMP3 co-expression produces an adrenomedullin receptor.
- RAMPs are relatively small (148-175 amino acids) proteins containing a single predicted membrane spanning domain, a large extracellular domain, and a short cytoplasmic domain. The molecular function of RAMPs includes cell-surface targeting and may involve direct ligand binding or indirect modulation of CRLR conformation, or both.
- CGRP receptor in which small molecule CGRP receptor antagonists display potency similar to that for the human CGRP receptor.
- Such a mutant will be useful in both various screening assays which are known in the art, such as cell based assays, receptor binding assays and/or radioligand binding assays, as well as the generation of transgenic animals which provide for this humanized CGRP receptor activity.
- polynucleotide which encodes a humanized version of the receptor-activity- modifying protein 1 (RAMPl).
- the present invention further relates to non-human animal cells, non-human transgenic animals, such as founders and littermates, especially transgenic "knock-in” animals, wherein the endogenous gene encoding RAMPl has been engineered (i.e., "humanized") to provide for a CGRP receptor pharmacological profile similar to human CGRP receptor.
- a preferred transgenic animal for the construction of such a targeted "knock-in” is a mouse.
- the present invention relates to isolated or purified mammalian nucleic acid molecules which encode a chimeric, hybrid and/or mutant version of a mammalian RAMPl protein, wherein such a derivative RAMPl protein comprises the respective mammalian amino acid sequence at least from about amino acid 1 to amino acid 65 and from about amino acid 113 to about amino acid 148, wherein the region corresponding from about amino acid 66 to amino acid 112 is at least partially derived from the human RAMPl coding region.
- the present invention further relates to isolated or purified mammalian nucleic acid molecules which encode a chimeric, hybrid and/or mutant version of a mammalian RAMPl protein, wherein such a derivative RAMPl protein at least comprises a nucleotide change which results in an alteration of amino acid residue 74 to a tryptophan residue, which results in a humanized mammalian form of RAMPl, exemplified herein by, but not limited to, the nucleic acid molecules disclosed as SEQ ID NOs 1, 3, 5 and 7.
- the present invention also relates to fragments or portions of a humanized RAMPl nucleotide sequence which encompasses the region which encodes the "humanizing" amino acid residue, namely the amino acid residue which corresponds to amino acid 74 of the human RAMPl protein and which has been altered to encode a tryptophan residue in the respective mammalian RAMPl nucleotide sequence, including but not limited to such fragments generated from SEQ ID NOs 1, 3, 5 and 7 which encompass the region encoding amino acid residue 74, shown herein to be responsible for "humanization" of the expressed mammalian RAMPl protein.
- the present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which have been transformed or transfected to contain the nucleic acid molecules disclosed throughout this specification and which encode a humanized version of a CGRP receptor and associated fragment thereof, substantially purified forms of a humanized version of a CGRP receptor, recombinant membrane fractions comprising these proteins (e.g., active CGRP receptors comprising CRLR and humanized RAMPl proteins), associated mutant proteins, and methods associated with identifying compounds which specifically modulated human CGRP utilizing the humanized version of CGRP receptor in various assays.
- recombinant vectors and recombinant host cells both prokaryotic and eukaryotic, which have been transformed or transfected to contain the nucleic acid molecules disclosed throughout this specification and which encode a humanized version of a CGRP receptor and associated fragment thereof, substantially purified forms of a humanized version of a CGRP receptor,
- the present invention also relates to a substantially purified form of a humanized RAMPl protein, including but not limited to a substantially purified, fully processed (including proteolytic processing, glycosylation and/or phosphorylation), mature humanized RAMPl protein obtained from a recombinant host cell.
- the present invention further relates to a substantially purified membrane preparation, partially purified membrane preparation, or cell lysate which has been obtained from a recombinant host cell transformed or transfected with a DNA expression vector which comprises and appropriately expresses a humanized RAMPl protein.
- a substantially purified membrane preparation, partially purified membrane preparation, or cell lysate which has been obtained from a recombinant host cell transformed or transfected with a DNA expression vector which comprises and appropriately expresses a humanized RAMPl protein.
- a DNA expression vector which comprises and appropriately expresses a humanized RAMPl protein.
- it is preferred that such membrane preparations comprise both a respective mammalian CRLR and RAMPl protein, so as to form an active, humanized CGRP receptor.
- the present invention also relates to biologically active fragments and/or mutants of a humanized RAMPl protein, comprising and/or consisting of the amino acid sequence as set forth in SEQ ID NOs: 2, 4, 6, and/or 8.
- the present invention also relates to polyclonal and monoclonal antibodies raised against forms of humanized RAMPl, a biologically active fragment of humanized RAMPl, and/or a CGRP receptor complex which comprises a humanized RAMPl.
- the present invention also relates to isolated nucleic acid molecules which encode humanized RAMPl fusion constructs.
- It is an object of the present invention to provide an isolated nucleic acid molecule (including but not limited to SEQ ID NOs:l, 3, 5, and/or 7) which encodes a humanized version of RAMPl , or fragments, mutants or derivatives of RAMPl , as set forth in SEQ ID NOs: 2, 4, 6 and 8, respectively.
- Any such polynucleotide includes but is not necessarily limited to nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which express a protein or protein fragment, which upon co-expression with a mammalian CRLR protein, may exhibit pharmacological properties similar to the human CGRP receptor.
- the RAMPl protein of the present invention be co-expressed with a mammalian form of CRLR.
- the recombinant host cell be from a eukaryotic host cell line, such as a mammalian cell line.
- isolated or purified nucleic acid molecule means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids.
- substantially free from other nucleic acids or “substantially purified” or “isolated nucleic acid” or “purified nucleic acid” also refer to a DNA molecules which comprises a coding region for a humanized RAMPl protein that has been purified away from other cellular components.
- a humanized RAMPl DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-humanized RAMPl nucleic acid molecules.
- Whether a given humanized RAMPl preparation is substantially free from other nucleic acids can be determined by such conventional techniques of assessing nucleic acid purity as, e.g., agarose gel electrophoresis combined with appropriate staining methods, e.g., ethidium bromide staining, or by sequencing.
- substantially free from other proteins or “substantially purified” means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other proteins.
- a humanized RAMPl protein preparation that is substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of humanized RAMPl proteins.
- Whether a given humanized RAMPl protein preparation is substantially free from other proteins can be determined by such conventional techniques of assessing protein purity as, e.g., sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, e.g., silver staining or immunoblotting.
- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
- detection methods e.g., silver staining or immunoblotting.
- isolated humanized RAMPl protein or “purified humanized RAMPl protein” also refer to humanized RAMPl protein that has been isolated from a natural source. Use of the term “isolated” or “purified” indicates that humanized RAMPl protein has been removed from its normal cellular environment.
- an isolated humanized RAMPl protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally.
- isolated does not imply that an isolated humanized RAMPl protein is the only protein present, but instead means that an isolated humanized RAMPl protein is substantially free of other proteins and non- amino acid material (e.g., nucleic acids, lipids, carbohydrates) naturally associated with the humanized RAMPl protein in vivo.
- a humanized RAMPl protein that is recombinantly expressed in a prokaryotic or eukaryotic cell and substantially purified from this host cell which does not naturally (i.e., without intervention) express this RAMPl protein is of course "isolated humanized RAMPl protein" under any circumstances referred to herein.
- a humanized RAMPl protein preparation that is an isolated or purified humanized RAMPl protein will be substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-humanized RAMPl proteins.
- “functional equivalent” or “biologically active equivalent” means a protein which does not have exactly the same amino acid sequence as naturally occurring or humanized RAMPl , due to alternative splicing, deletions, mutations, substitutions, or additions, but retains substantially the same biological activity as the respective naturally occurring or humanized RAMPl.
- Such functional equivalents will have significant amino acid sequence identity with naturally occurring or humanized RAMPl, especially with the presence of the "humanizing" tryptophan codon at amino acid residue 74.
- the term "functional” is used to describe a gene or protein that, when present in a cell or in vitro system, performs normally as if in a native or unaltered condition or environment. Therefore, a gene which is not functional (i.e., “non-functional”, “disrupted”, “altered”, or the like) will encode a protein which does not function as a wild type, native or non-altered protein, or encodes no protein at all.
- non-functional gene may be the product of a homologous recombination event as described herein, where a non-functional gene is targeted specifically to the region of the target chromosome which contains a functional form of the gene, resulting in a "knock-out" of the wild type or native gene.
- a “modulator” is a compound that causes a change in the expression or activity of a mammalian CGRP receptor, such as a human or humanized CGRP receptor, or causes a change in the effect of the interaction of the respective receptor with its ligand(s), or other protein(s), such as an antagonist or agonist.
- rodent relates to a species which is a member of the order Rodentia, having a single pair of upper and lower incisors for gnawing, wherein the teeth grow continuously and a gap is evident between the incisors and grinding molars.
- Preferred examples include for generation of transgenic animals include, but are not limited to, Rattus norvegicus, Rattus rattus, and Mus musculus.
- rat relates to animals which from the point of systemic zoology belong to the genus Rattus.
- the transgenic animals of the present invention may be generated from any species of the genus Rattus, including but not limited to Rattus norvegicus and Rattus rattus.
- mae relates to animals which from the point of systemic zoology belong to the genus Mus.
- the transgenic animals of the present invention may be generated from any species of the genus Mus, such as the house mouse, Mus musculus.
- cynomolgous or “cyno” refers to a non-human primate also referred to as a macaque, from the genus Macaca, such as but not limited to Macaca cynomolgus.
- marmoset is known to include non-human primates which possess soft fur and claws (instead of nails) on all digits except the great toe, belonging to the family Callithricidae.
- pig is interchangeable with the term “porcine.”
- the term “mammalian” will refer to any mammal, including a human being, except in the context of utilizing a —mammalian— RAMPl sequence to generate a —humanized— RAMPl protein. In that context, of course, the human sequence is meant to be excluded.
- Figure 1 shows the amino acid alignment of human, rat and mouse wild type RAMPl protein sequences.
- Amino acid residue 74 is the target amino acid for humanization of mammalian RAMPl protein sequences such as the mouse and rat sequence.
- Figure 2 shows the chemical structure of several CGRP antagonists, BIBN4096BS, Compound 1 and Compound 2.
- FIG 3 shows the constructed RAMPl Chimeras and RAMPl Mutagenesis.
- Chimera 1 was constructed by replacing the first 66 amino acids of rat RAMPl with the human sequence.
- Chimera 2 was generated in a similar fashion by replacing the first 112 amino acids of rat RAMPl with those from human RAMPl. Hashed regions indicate human RAMPl sequence; the remaining unfilled areas represent rat peptide sequence. Mutagenesis of rat RAMPl at position 74 produced a single RAMPl point mutant.
- Figure 4 shows the alignment of amino acids 66-112 of RAMPl from human, marmoset, rat, mouse and pig. A partial marmoset RAMPl clone was generated as described in Example 1.
- FIG. 5 shows Western blotting analysis of rCRLR co-expressed with rRAMPl(rat RAMPl) and hRAMPl (human RAMPl).
- the membranes from the competitive binding experiments including rCRLR transfected with empty vector (pcDNA3.1), were treated with Peptide-N-Glycosidase F (F), Endoglycosidase Fl (Fl), or no enzyme. Samples were separated by SDS-PAGE, followed by western blot analysis with anti-rat CRLR antibodies.
- the present invention relates to an isolated or purified nucleic acid molecule (polynucleotide) which encodes a humanized version of a calcitonin gene-related peptide (CGRP) receptor, which comprises the G-protein coupled receptor calcitonin- receptor-like receptor (CRLR) and the receptor-activity-modifying protein-1 (RAMPl).
- CGRP calcitonin gene-related peptide
- CRLR G-protein coupled receptor calcitonin- receptor-like receptor
- RAMPl receptor-activity-modifying protein-1
- the present invention relates to isolated or purified vertebrate, and preferably mammalian, nucleic acid molecules which encode derivative, humanized versions of the CGRP receptor, namely via DNA molecules which encode chimeric, hybrid or mutant derivatives of a mammalian RAMPl sequence, which are shown herein to be responsible for the "humanization" of the CGRP receptor upon association with a vertebrate (and again, preferably a mammalian) CRLR receptor protein.
- the CRLR and RAMPl DNA molecules disclosed herein may be co-transfected into a host cell of choice wherein the recombinant host cell provides a source for substantial levels of an expressed functional, humanized version of a CGRP receptor.
- these recombinantly expressed humanized CGRP receptor proteins form a receptor complex in which small molecule CGRP receptor antagonists display potency similar to that for a "wild type" human CGRP receptor.
- Such mutant receptors will be useful in cell based assays, receptor binding assays and/or radioligand binding assays, and, as noted below, in the generation of transgenic animals which provide for this humanized CGRP receptor activity.
- non-human animal cells non-human transgenic animals, such as founders and littermates, especially transgenic "knock-in" animals, wherein the endogenous gene encoding RAMPl has been engineered (i.e., "humanized") to provide for a CGRP receptor pharmacological profile similar to human CGRP receptor.
- non-human transgenic animals will preferably provide for an altered genotype (endogenous CRLR and "humanized” RAMPl), which will provide for a phenotype whereby the pharmacological profile of the non-human transgenic animal in regard to modulators of CGRP will mimic the human form of CGRP receptor.
- non-human transgenic animals may be contemplated in view of the finding disclosed herein that alteration of a single amino acid residue in a non-human RAMPl sequence (such as rat, mouse and pig, as shown herein, as well as additional species, such as cyno and canine) results in a "humanized" version of RAMPl when complexed with a mammalian version of CRLR.
- a non-human RAMPl sequence such as rat, mouse and pig, as shown herein, as well as additional species, such as cyno and canine
- the species-specific pharmacology of known antagonists is shown herein to be localized to the region at or around amino acid residue 74 of human RAMPl (a tryptophan residue), such that non-human RAMPl forms may be generated and used to generate transgenic animals which express the humanized version along with or instead of the endogenous RAMPl protein.
- the present invention therefore relates to isolated or purified nucleic acid molecules which encode a chimeric, hybrid and/or mutant version of a RAMPl protein where such a protein is functional (i.e., when co-expressed with CRLR will exhibit predicted pharmacological properties), and furthermore wherein such a protein is humanized by virtue of altering the amino acid that corresponds to human amino acid residue 74 to a tryptophan residue.
- a nucleic acid molecule is part of the present invention whether it encodes a chimeric, hybrid or various mutant protein, so long as amino acid 74 has been altered from its native residue to the human residue, namely tryptophan.
- the present invention further relates to isolated or purified nucleic acid molecules which encode a chimeric, hybrid and/or mutant version of a RAMPl protein, wherein such a derivative RAMPl protein comprises the respective amino acid sequence at least from about amino acid 1 to amino acid 65 and from about amino acid 113 to about amino acid 148, wherein the region corresponding from about amino acid 66 to amino acid 112 is at least partially derived from the human RAMPl coding region.
- Such DNA molecules will encode "humanized" RAMPl proteins which, when co-expressed with a CRLR gene, or functional derivative thereof, will result in a CGRP receptor which mimics human CGRP receptor pharmacological properties.
- the present invention further relates to isolated or purified nucleic acid molecules which encode a chimeric, hybrid and/or mutant version of a RAMPl protein, wherein such a derivative RAMPl protein at least comprises a nucleotide change which results in an alteration of amino acid residue 74 to a tryptophan residue, which results in a humanized form of RAMPl.
- a specific embodiment of the present invention relates to an isolated or purified nucleic acid molecule from rat wherein the codon for amino acid residue 74 is altered from a lysine residue to a tryptophan residue.
- Still another specific embodiment of the present invention relates to an isolated or purified nucleic acid molecule from porcine (pig) wherein the codon for the amino acid residue corresponding to human residue 74 is altered from a arginine residue to a tryptophan residue (i.e., a "R74W" mutant).
- the present invention further relates to an isolated nucleic acid molecule (polynucleotide) which encodes mRNA which expresses a humanized RAMPl protein, this DNA molecule comprising the nucleotide sequence disclosed herein in Table 1 and listed as SEQ ID NO: l (rat), SEQ ID NO:3 (mouse), SEQ ID NO:5 (a partial sequence from cyno) and SEQ ID NO:7 (a partial sequence from porcine (pig)).
- Table 1 discloses the nucleotide and predicted amino acid sequences of these various mammalian RAMPl sequences which, when expressed as a full length RAMPl protein, correspond to a "humanized" form of RAMPl .
- the present invention also relates to biologically active fragments or mutants of SEQ ID NOs: 1, 3, 5 and 7 which encode mRNA expressing a humanized RAMPl protein.
- Any such biologically active fragment and/or mutant will encode either a protein or protein fragment which at least substantially mimics the pharmacological properties of human RAMPl, including but not limited to the humanized RAMPl proteins as set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO: 8, with SIDs 6 and 8 representing partial sequences which span the region manipulated for humanization of the respective RAMPl protein.
- any such polynucleotide includes but is not necessarily limited to chimeric constructs (including but not limited to the exemplified chimeric constructs described herein), hybrid constructs, nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations such that these mutations encode mRNA which may co-express a functional humanized RAMPl with a mammalian CRLR protein in a eukaryotic cell so as to be useful for screening for agonists and/or antagonists of CGRP activity.
- preferred aspects of this portion of the present invention are disclosed in Table 1 as SEQ ID NOs:l; 3 and 5, all of which encode a humanized version of RAMPl.
- the isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide.
- DNA deoxyribonucleic acid molecule
- cDNA complementary DNA
- synthetic DNA such as a synthesized, single stranded polynucleotide.
- the isolated nucleic acid molecule of the present invention may also include a ribonucleic acid molecule (RNA).
- the present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this specification and which encode a humanized version of a CGRP receptor and associated fragment thereof, substantially purified forms of associated humanized version of a CGRP receptor, recombinant membrane fractions comprising these proteins (e.g., active CGRP receptors comprising CRLR and humanized RAMPl proteins), associated mutant proteins, and methods associated with identifying compounds which specifically modulated human CGRP receptor utilizing the humanized version of RAMPl in various assays.
- prokaryotic and eukaryotic which contain the nucleic acid molecules disclosed throughout this specification and which encode a humanized version of a CGRP receptor and associated fragment thereof, substantially purified forms of associated humanized version of a CGRP receptor, recombinant membrane fractions comprising these proteins (e.g., active CGRP receptors comprising CRLR and humanized RAMPl proteins
- the present invention also relates to a substantially purified form of a humanized RAMPl protein, which comprises the amino acid sequence disclosed in Table 1 (e.g., SEQ ID NOs:2, 4, 6 and 8).
- the invention further relates to a humanized RAMPl protein which consists of the amino acid sequence disclosed in Table 1 (e.g., SEQ ID NOs:2, 4, 6 and 8).
- a humanized RAMPl protein which consists of the amino acid sequence disclosed in Table 1 (e.g., SEQ ID NOs:2, 4, 6 and 8).
- vertebrate sequences are within the scope of the invention, mammalian sequences, including but not limited to those exemplified herein, are preferred.
- Another preferred aspect of the present invention relates to a substantially purified, fully processed (including proteolytic processing, glycosylation and/or phosphorylation), mature humanized RAMPl protein obtained from a recombinant host cell containing a DNA expression vector comprising nucleotide sequence as set forth in SEQ ID NOs: 1, 3, 5 and 7 which express the respective humanized RAMPl protein.
- the recombinant host cell be a eukaryotic host cell, such as a mammalian cell line.
- Another aspect of the present invention relates to a substantially purified membrane preparation, partially purified membrane preparation, or cell lysate which has been obtained from a recombinant host cell transformed or transfected with a D A expression vector which comprises and appropriately expresses a complete open reading frame as set forth, for example, in SEQ ID NOs: 1, 3, 5 and 7, which results in a functional form of the respective humanized RAMPl protein.
- These recombinant membranes will comprise humanized RAMPl proteins such as those disclosed in Table 1 (i.e., SEQ ID NOs: 2, 4, 6 and 8), or additional equivalents which results in a humanized form of RAMPl, namely mammalian RAMPl proteins wherein the amino acid residue corresponding to human amino acid residue 74 has been altered to code for a tryptophan residue.
- humanized RAMPl proteins such as those disclosed in Table 1 (i.e., SEQ ID NOs: 2, 4, 6 and 8), or additional equivalents which results in a humanized form of RAMPl, namely mammalian RAMPl proteins wherein the amino acid residue corresponding to human amino acid residue 74 has been altered to code for a tryptophan residue.
- a preferred aspect of this portion of the present invention relates to a substantially purified membrane preparation, partially purified membrane preparation, or cell lysate which has been obtained from a recombinant host cell transformed or transfected with a DNA expression vector which comprises and appropriately expresses a humanized RAMPl protein as described throughout this specification, in conjunction with a DNA expression vector which comprises and appropriately expresses a mammalian CRLR GPCR protein.
- mammalian nucleotide sequences which may be utilized for such a purpose included but are not limited to the human, rat and mouse nucleic acid molecules disclosed in Table 2 and set forth as SEQ ID NOs: 7, 9, and 11, which results in a functional form of a mammalian CRLR GPCR which, when co-expressed with a humanized RAMPl protein, will be useful to screen for modulators which effect the human CGRP receptor.
- the subcellular membrane fractions and/or membrane-containing cell lysates from the recombinant host cells both prokaryotic and eukaryotic as well as both stably and transiently transformed cells) contain the functional and processed proteins encoded by the nucleic acid molecules disclosed herein.
- This recombinant-based membrane preparation will comprise a mammalian CRLR protein and a humanized RAMPl protein which is essentially free from contaminating proteins.
- These subcellular membrane fractions will comprise "humanized" CGRP receptors which function efficiently for the screening of modulators (e.g., agonists and especially antagonists) of the human CGRP receptor at levels which are at least similar to or possibly substantially above endogenous levels. Any such "humanized" CGRP receptor-containing membrane preparation will be useful in various assays to select for modulators of the respective CGRP receptor.
- a preferred eukaryotic host cell of choice to express the CGRP receptor of the present invention is a mammalian cell line.
- the present invention also relates to biologically active fragments and/or mutants of a humanized RAMPl protein, comprising the amino acid sequence as set forth in SEQ ID NOs: 2, 4, 6 or 8, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for screening for selective modulators, including but not limited to agonists and/or antagonists for human CGRP receptor pharmacology.
- a preferred aspect of the present invention is disclosed in Table 1 as SEQ ID NOs:2, 4, 6 and 8, respective amino acid sequences which are mammalian RAMPl proteins, or portions thereof, which have been "humanized” solely by altering amino acid residue 74 to a tryptophan ("Trp" or "W") residue.
- Trp tryptophan
- co-expression of a humanized RAMPl protein of the present invention along with a mammalian CRLR protein will be useful in screening for antagonists of the CGRP receptor.
- the present invention also relates to polyclonal and monoclonal antibodies raised against forms of humanized RAMPl, a biologically active fragment of humanized RAMPl, or a CGRP receptor complex which comprises a humanized RAMPl.
- the present invention also relates to isolated nucleic acid molecules which encode humanized RAMPl fusion constructs (as well as the substantially purified protein expressed within and recovered from the respective host cell which houses the fusion construct, most likely in the form of a DNA expression vector), including but not limited to fusion constructs which express a portion of humanized RAMPl to various markers, including but in no way limited to GFP (Green fluorescent protein), the MYC epitope, GST, Fc, Flag, HA, and His-tag.
- GFP Green fluorescent protein
- any such fusion construct will comprise at least a portion of the RAMPl open reading frame which encodes for the alteration at amino acid 74 to a tryptophan residue, such that the respective fusion protein will exhibit human-like pharmacological properties when complexed with a mammalian CRLR protein.
- the heterodimeric CGRP receptor requires co-expression of calcitonin receptor-like receptor (CRLR) and an accessory protein called receptor activity modifying protein 1, or RAMPl.
- CRLR calcitonin receptor-like receptor
- RAMPl receptor activity modifying protein
- Several small molecule CGRP receptor antagonists have been shown to exhibit marked species selectivity, with >100-fold higher affinities for the human CGRP receptor than for receptors from other species. It is shown herein that species selectivity of CGRP modulators is determined exclusively by RAMPl.
- amino acid position 74 of RAMPl is responsible for the observed species selectivity of several known antagonists of the CGRP receptor, suggesting that that the affinity of small molecule antagonists can be affected by a single amino acid change and that these antagonists may interact directly with RAMPl.
- the identification of a single amino acid mutation that can convert the mouse CGRP receptor into one that displays human-like pharmacology shows that a humanized CGRP receptor mouse may be created by a "knock-in" strategy, wherein lysine-74 is replaced with tryptophan by various techniques well known in the art.
- Such a humanized non-human transgenic animal e.g., a transgenic mouse
- the present invention relates to a transgenic non-human animal, such as a founder animal or subsequent littermate, wherein both alleles of the endogenous RAMPl gene have been humanized, as well as heterozygous transgenic non-human animals wherein a single endogenous RAMPl allele has been humanized and to non-human transgenic animal comprising wild type endogenous RAMPl alleles in addition to at least one humanized RAMPl allele stably integrated within the respective target genome.
- the present invention relates to animal cells, non-human transgenic embryos, non-human transgenic animals and non-human transgenic littermates which are homozygous for humanized RAMPl and whereby endogenous RAMPl has been disrupted, namely by replacement of the endogenous RAMPl coding region, or portion thereof, by direct gene targeting within the respective target genome.
- the present invention also extends to animal cells, non-human transgenic embryos, non-human transgenic animals (such as founder animals and transgenic littermates) which are heterozygous for a functional RAMPl gene native to that animal. Namely, the heterozygosity referring the one functional, endogenous RAMPl gene and one functional, humanized RAMPl gene.
- the present invention relates to animal cells, non-human transgenic embryos and non-human transgenic littermates having at least one and possibly multiple humanized RAMPl genes being randomly inserted within the target genome, such that both functional endogenous and humanized RAMPl proteins may be expressed.
- the transgenic animals of the present invention can be used in the study of the effect of modulators, especially antagonists, of the CGRP receptor.
- transgenic non-human animal will be especially useful for in vivo efficacy and receptor occupancy studies for testing of CGRP receptor modulators, especially antagonists, for treatment of various disorders, including but not limited to migraine headaches, pain, menopausal hot flash, migraine prophylaxis, chronic tension type headache, cluster headache, neurogenic or chronic inflammation, gastrointestinal disorders, type 2 diabetes and cardiovascular disorders (via agonizing the CGRP receptor).
- CGRP receptor modulators especially antagonists
- various disorders including but not limited to migraine headaches, pain, menopausal hot flash, migraine prophylaxis, chronic tension type headache, cluster headache, neurogenic or chronic inflammation, gastrointestinal disorders, type 2 diabetes and cardiovascular disorders (via agonizing the CGRP receptor).
- RAMPl will result in a species in which small molecule CGRP receptor antagonists display potency similar to that for the human CGRP receptor.
- the non-human transgenic animal of the present invention may also provide cells for culture, for in vitro studies. Therefore, in particular embodiments of the present invention, cell lines are produced and cells isolated from any of the animals produced in the steps described herein.
- An aspect of this portion of the invention is a method to obtain an animal wherein the endogenous RAMPl gene native to the animal has been replaced by "knock-in” technology such that a humanized form of RAMPl has replaced the endogenous RAMPl allele(s).
- a RAMPl gene that naturally occurs in the animal is referred to as the native gene, endogenous gene and/or "wild-type" gene. It is preferred that expression of a non- native RAMPl gene (e.g., a "humanized” RAMPl gene) take place in a transgenic animal in the absence of a native RAMPl gene.
- transgenic "knock-in" non-human animal such as a transgenic mouse
- the method includes providing a gene for a humanized form of RAMPl in the form of a transgene and targeting the transgene into a chromosome of the animal at the place of the native RAMPl gene or at another chromosomal location.
- the transgene can be introduced into the embryonic stem cells by a variety of methods known in the art, including electroporation, microinjection, and lipofection.
- transgene- targeted embryonic stem cells can be co-incubated with fertilized eggs or morulae followed by implantation into females. After gestation, the animals obtained are chimeric founder transgenic animals.
- the founder animals can be used in further embodiments to cross with wild-type animals to produce Fl animals heterozygous for the altered RAMPl gene.
- these heterozygous animals can be interbred to obtain the viable transgenic embryos whose somatic and germ cells are homozygous for the altered, humanized RAMPl.
- the heterozygous animals can be used to produce cells lines.
- the animals are mice or rat. Therefore, a preferred aspect of this portion of the present invention is a transgenic non-human animal which expresses a non -native, humanized RAMPl protein on a native RAMPl null background.
- the animal can be heterozygous (i.e., having a different allelic representation of a gene on each of a pair of chromosomes of a diploid genome, such as native RAMPl/humanized RAMPl), homozygous (i.e., having the same representation of a gene on each of a pair of chromosomes of a diploid genome, such as humanized RAMPl/humanized RAMPl) for the altered RAMPl gene, hemizygous (i.e., having a gene represented on only one of a pair of chromosomes of a diploid genome, preferably a humanized version of RAMPl), or homozygous for the humanized RAMPl gene.
- heterozygous i.e., having a different allelic representation of a gene on each of a pair of chromosomes of a diploid genome, such as native RAMPl/humanized RAMPl
- homozygous i.e., having the same representation of a gene on
- the animal is a mouse or a rat, with mouse being especially preferred.
- the targeted or randomly inserted humanized RAMPl gene may be operably linked to a promoter.
- operably linked is used to denote a functional connection between two elements whose orientation relevant to one another can vary.
- a promoter can be operably linked to the coding sequence of a gene to direct the expression of the coding sequence while placed at various distances from the coding sequence in a genetic construct.
- Further embodiments are cell lines and cells derived from animals of this aspect of the invention.
- the non-human transgenic animals of the present invention include non-human mammalian species which are candidates for humanization, including but not limited to transgenic mice, transgenic rats, as well as non-human primates which are candidates for RAMPl humanization. Transgenic mice are preferred.
- the present invention especially relates to analysis of the complex function(s) of the CGRP receptor.
- the native wild type gene is selectively replaced via targeted gene delivery or it resides within the same genome by random integration of a humanized RAMPl gene in totipotent ES cells and used to generate the transgenic mice of the present invention.
- the present invention relates to diploid animal cells, non-human transgenic embryos, non-human transgenic animals and non-human transgenic founders and/or transgenic littermates which are heterozygous or homozygous for a disrupted RAMPl gene and/or insertion of a humanized RAMPl gene.
- the cells, embryos and non-human transgenic animals contain two chromosome alleles for humanized RAMPl wherein at least one of the wild type RAMPl alleles is mutated such that less than wild-type levels of RAMPl activity is produced.
- the diploid cell, embryo or non-human transgenic animal homozygous for a humanized RAMPl gene, wherein a humanized RAMPl gene has been targeted to replace the wild type allele may show at least from about 50%, and preferably about 100% reduction in wild type RAMPl activity (measured by the loss of "wild type" pharmacological characteristics of the endogenous CGRP receptor) and a concomitant CGRP receptor activity which mimics human CGRP receptor pharmacology, as compared to a wild type diploid cell.
- a diploid mouse cell, embryo or non-human transgenic mouse generated herein which is heterozygous for a disrupted RAMPl gene may show at least from about 10% to about 100% reduction in endogenous RAMPl activity compared to a wild type diploid cell. It is within the purview of the artisan of ordinary skill to use known molecular biology techniques to measure the level of transcription, expression and/or functional CRLR/RAMPl activity in mouse cell homozygous, heterozygous or hemizygous for a humanized RAMPl gene.
- the present invention especially relates to analysis of the complex function(s) of the CGRP receptor by generating homozygous, heterozygous or hemizygous transgenic mice and studying how various potential modulators interact within these manipulated animals.
- the assay is performed by providing an animal of the present invention (especially a transgenic animal wherein a humanized RAMPl gene has replaced the endogenous RAMPl gene at both alleles), exposing the animal to a compound (preferably a potential antagonist of CGRP receptor activity), and measuring the effect of said compound on biochemical and physiological responses related to CGRP activity, or lack thereof. The measurement can be compared to these measurements in a genetically similar or identical animal that is not exposed to the compound.
- a type of target cell for transgene introduction is preferably the embryonic stem cell (ES), especially when generating a transgenic mouse, where culturing of ES cells has been particularly successful.
- ES cells can be obtained from pre- implantation embryos cultured in vitro and fused with embryos (Evans et al., 1981, Nature 292: 154-156; Bradley et al., 1984, Nature 309: 255-258; Gossler et al., 1986, Proc. Natl. Acad. Sci. USA 83: 9065-9069; and Robertson et al., 1986, Nature 322: 445- 448).
- Transgenes can be efficiently introduced into the ES cells by a variety of standard techniques such as D ⁇ A transfection, microinjection, or by retrovirus-mediated transduction.
- the resultant transformed ES cells can thereafter be combined with blastocysts from a non-human animal.
- the introduced ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal (Jaenisch, 1988, Science 240: 1468-1474).
- the use of gene-targeted ES cells in the generation of gene- targeted transgenic mice was described in 1987 (Thomas et al., Cell 51:503-512, (1987)) and is reviewed elsewhere (Frohman et al., Cell 56:145-147 (1989); Capecchi, Trends in Genet.
- the methods for evaluating the targeted recombination events as well as the resulting knockout mice are also readily available and known in the art. Such methods include, but are not limited to DNA (Southern) hybridization to detect the targeted allele, polymerase chain reaction (PCR), polyacrylamide gel electrophoresis (PAGE), in situ hybridization, RNA/Northern hybridization and Western blots to detect DNA, RNA and protein. It is now well known in the art that various strategies are readily available to the artisan to generated transgenic animals, such as transgenic "knock-in" animals.
- BAC recombination technologies include but are not limited to the teachings of Shizuya, et al., 1992, Proc. Natl. Acad. Sci. USA 89: 8794-8797 (introduction of BAC vectors); Zhang et al., 1998, Nature Genetics 20: 123-128 and Muyrers, et al., 2001, Nucleic Acids Research 27(6): 1555-1557 (modification of BAC clones via plasmid based expression of recA/recT proteins from the Rac phage or rad ⁇ or rad ⁇ from ⁇ phage, respectively, for a review see also Muyrers et al.
- this technology may be utilized to identify a RAMPl genomic clone (such as a mouse genomic clone), modifying such a genomic clone so as to humanize the coding sequence (i.e., Lys to Trp at amino acid residue 74; where, for example, in generating a transgenic mouse, the only modification required will be the mutagenesis of 2 nucleotides to change the Lysine (AAG) to a Tryptophan (TGG), which results in introduction of a BstNI restriction site [from CCAAG to CCTGG], which is helpful for screening purposes) and to then deliver and stably incorporate, either by homologous or non-homologous recombination, to an ES cell or pronucleus.
- a RAMPl genomic clone such as a mouse genomic clone
- modifying such a genomic clone so as to humanize the coding sequence (i.e., Lys to Trp at amino acid residue 74; where, for example
- mouse sequence consortium (MSC) database is queried with RAMPl nucleotide sequence.
- An initial search resulted in 2 mouse genomic sequence "hits” which were identified as mouse RAMPl. These 2 hits encoded putative exons 2 and 3 of mouse RAMPl. Putative exons 2 and 3 were found on a 712 bp fragment and a 1339 bp contig of 2 fragments, respectively. Putative exon 3 contains amino acid residue 74.
- This information can be utilized to design a probe for mouse BAC library screening to obtain putative exon 3 and the surrounding intronic sequence for targeting vector construction.
- the genomic organization appears to be conserved between human and mouse with intron/exon borders located at similar residues (Derst et al., 2000, Cytogenet Cell Genet 90: 115-118).
- transgenic non-human animal models as described herein will be useful to screen any potential modulator of CGRP receptor activity (e.g., antagonists or agonists), including but not necessarily limited to peptides, proteins, or non- proteinaceous organic or inorganic molecules.
- the present invention relates to processes for the production of the transgenic animals of the present invention and their offspring and their use for pharmacological testing.
- the invention further relates to methods of determining the selectivity and activity of potential modulators (especially antagonists) of humanized CGRP receptors expressed within transgenic animals of the present invention by administering a test compound or compounds to the transgenic animal and measuring the effect of the compound on the activity of the humanized CGRP receptor.
- the present invention relates to various occupancy assays which may be run in conjunction with the transgenic non -human animals of the present invention.
- a transgene is a genetic construct including a gene.
- the transgene of interest is incorporated into the target genome of the target cell, thus being introduced into their germ cells and/or somatic cells such that it is stably incorporated and is capable of carrying out a desired function.
- a chromosome is the preferred target for stable incorporation of a transgene into the target animal
- the term "genome” refers to the entire DNA complement of an organism, including nuclear DNA (chromosomal or extrachromosomal DNA) as well as mitochondrial DNA, which is localized within the cytoplasm of the cell.
- the transgenic non-human animal of the present invention will stably incorporate one or more transgenes in either/or of the mouse germ cells or somatic cells (preferably both), such that the expression of the transgene (e.g., a humanized form of mammalian RAMPl) achieves the desired effect of presenting a specific receptor occupancy model for modulators of human RAMPl as well as providing for an pharmacodynamic animal model system to study the selectivity of test compounds to modulate the human RAMPl receptor. It is preferable to introduce the transgene into a germ line cell, thereby conferring the ability to transfer the information to offspring. If offspring in fact possess some or all of the genetic information, then they, too, are transgenic animals.
- the transgene e.g., a humanized form of mammalian RAMPl
- transgenic animal may include all mammals, except that when referring to transgenic animals, the use of this term excludes humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages.
- a "transgenic animal” is an animal containing one or more cells bearing genetic information received, directly or indirectly, by deliberate genetic manipulation at a subcellular level, such as by microinjection , targeted gene delivery such as by homologous recombination, or infection with recombinant virus.
- this introduced DNA molecule i.e., transgene
- transgenes As used herein in reference to transgenic animals of this invention, we refer to "transgenes" and “genes".
- a gene is a nucleotide sequence that encodes a protein, or structural RNA.
- the gene and/or transgene may also include genetic regulatory elements and/or structural elements known in the art.
- a transgene is a genetic construct including a gene. The transgene is integrated into one or more chromosomes in the cells in an animal by methods known in the art. Once integrated, the transgene is carried in at least one place in the genome, preferably a chromosome, of a transgenic animal.
- founder refers to a transgenic animal which develops from the microinjected egg. The founders are tested for expression of a functional gene by any suitable assay of the gene product.
- line refers to animals that are direct descendants of one founder and bearing one transgene locus stably integrated into their germline.
- inbred line refers to animals which are genetically identical at all endogenous loci. As used in the art, inbred lines may be used for including reproducibility from one animal to the next, ability to transfer cells or tissue among animals, and the ability to carry out defined genetic studies to identify the role of endogenous genes. Such inbred lines may be developed from such lines wherein the mice that are used for microinjection are members of established inbred strains.
- gene “genotype” is the genetic constitution of an organism. As used herein, the term “phenotype” is a collection of morphological, physiological and/or biochemical traits possessed by a cell or organism that results from the interaction of the genotype and the environment.
- phenotype is a biochemical trait wherein a non-native transgene has been introduced into the animal, thus altering its the genotypic profile, and whereby expression of this transgene(s) within the animal results in a new pharmacological selectivity to one or more chemical compounds, such a selectivity based on functional expression of the transgene(s) of interest.
- phenotypic expression relates to the expression of a transgene or transgenes which results in the production of a product, e.g., a polypeptide or protein, or alters the expression of the zygote's or the organism's natural phenotype.
- the transgene of interest is incorporated into the target genome of the target cell, thus being introduced into their germ cells and/or somatic cells such that it is stably incorporated and is capable of carrying out a desired function.
- a chromosome is the preferred target for stable incorporation of a transgene into the target animal
- the term "genome” refers to the entire DNA complement of an organism, including nuclear DNA (chromosomal or extrachromosomal DNA) as well as mitochondrial DNA, which is localized within the cytoplasm of the cell.
- the transgenic non- human animals of the present invention will stably incorporate one or more transgenes in either/or of the animal's germ cells or somatic cells (preferably both), such that the expression of the transgene (e.g., a functional, humanized version of RAMPl) achieves the desired effect of presenting a specific receptor occupancy model for modulators of a humanized CGRP receptor as well as providing for an pharmacodynamic animal model system to study the selectivity of test compounds to modulate a humanized CGRP receptor which comprises an endogenous CRLR protein and a humanized RAMPl protein. It is preferable to introduce the transgene into a germ line cell, thereby conferring the ability to transfer the information to offspring.
- the transgene e.g., a functional, humanized version of RAMPl
- transgenic animals may include all mammals, except that when referring to transgenic animals, the use of this term excludes humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages.
- a "transgenic animal” is an animal containing one or more cells bearing genetic information received, directly or indirectly, by deliberate genetic manipulation at a subcellular level, such as by microinjection , targeted gene delivery such as by homologous recombination, or infection with recombinant virus.
- this introduced DNA molecule i.e., transgene
- a targeted "knock-in" is performed whereby a humanized version of RAMPl is inserted and replaces the endogenous RAMPl coding region.
- the degeneracy of the genetic code is such that, for all but two amino acids, more than a single codon encodes a particular amino acid.
- This allows for the construction of synthetic DNA that encodes a humanized RAMPl protein where the nucleotide sequence of the synthetic DNA differs significantly from the nucleotide sequences disclosed herein, as exemplification but not limitations, but still encodes a humanized RAMPl protein.
- Such synthetic DNAs are intended to be within the scope of the present invention. If it is desired to express such synthetic DNAs in a particular host cell or organism, the codon usage of such synthetic DNAs can be adjusted to reflect the codon usage of that particular host, thus leading to higher levels of expression of the humanized RAMPl protein in the host.
- this invention is also directed to those DNA sequences which encode RNA comprising alternative codons which code for the eventual translation of the identical amino acid, as shown below:
- GCU C Cy
- the present invention discloses codon redundancy which may result in differing DNA molecules expressing an identical protein.
- a sequence bearing one or more replaced codons will be defined as a degenerate variation.
- Another source of sequence variation may occur through RNA editing, as discussed infra.
- Such RNA editing may result in another form of codon redundancy, wherein a change in the open reading frame does not result in an altered amino acid residue in the expressed protein.
- mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.
- DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally occurring peptide.
- Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or a receptor for a ligand.
- Identity is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity” per se has an art-recognized meaning and can be calculated using published techniques. See, e.g.,: (Computational Molecular Biology, Lesk, A. M., ed. Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds..
- identity is well known to skilled artisans (Carillo and Lipton, 1988, SIAM J Applied Math 48: 1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J.
- a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations or alternative nucleotides per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO:l.
- nucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence.
- mutations or alternative nucleotide substitutions of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
- RNA editing results in modification of an mRNA molecule such that use of that modified mRNA as a template to generate a cloned cDNA may result in one or more nucleotide changes, which may or may not result in a codon change.
- This RNA editing is known to be catalyzed by an RNA editase.
- Such an RNA editase is RNA adenosine deaminase, which converts an adenosine residue to an inosine residue, which tends to mimic a cytosine residue.
- polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO: 2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO:2.
- a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
- These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence of anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
- RNA editing may result in a codon change which will result in an expressed protein which differs in "identity” from other proteins expressed from “non-RNA edited” transcripts, which correspond directly to the open reading frame of the genomic sequence. Therefore, the concept of nucleic acid sequence identity is applicable to the present invention in the context that variations, other than "humanization” of amino acid residue 74, are within the scope of the present invention so long as those variations do not significantly effect the ability of the respective expressed RAMPl protein to mimic human RAMPl when associated with a mammalian CRLR protein.
- the present invention also relates to recombinant vectors and recombinant hosts, both prokaryotic and eukaryotic, which contain the substantially purified nucleic acid molecules disclosed throughout this specification.
- the nucleic acid molecules of the present invention encoding a RAMPl protein in whole or in part, can be linked with other DNA molecules, i.e, DNA molecules to which the RAMPl coding sequence are not naturally linked, to form "recombinant DNA molecules" which encode a respective RAMPl protein.
- the DNA molecules of the present invention can be inserted into vectors which comprise nucleic acids encoding RAMPl or a functional equivalent. These vectors may be comprised of DNA or RNA; for most cloning purposes DNA vectors are preferred.
- Typical vectors include plasmids, modified viruses, bacteriophage, cosmids, yeast artificial chromosomes, and other forms of episomal or integrated DNA that can encode a RAMPl protein. It is well within the purview of the skilled artisan to determine an appropriate vector for a particular gene transfer or other use. Therefore, as with many proteins, it is possible to modify many of the amino acids of RAMPl protein and still retain substantially the same biological activity as the wild type protein.
- this invention includes modified RAMPl polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as a respective, corresponding humanized RAMPl (i.e, wherein amino acid 74 is a tryptophan residue and any other changes do not significantly effect the ability of the altered RAMPl to mimic human pharmacological characteristics as the human CGRP receptor).
- the essence of the present invention is the ability to humanize a vertebrate RAMPl protein by altering the vertebrate RAMPl amino acid sequence at residue 74 to a tryptophan residue. Therefore, alteration of just a single amino acid resulted in a completely different, and now predictable, pharmacological profile for such a mutated protein.
- the present invention includes polypeptides where one or more additional amino acid substitutions has been made in SEQ ID NOs:2, 4, 6, and/or 8, wherein the polypeptides still retain substantially the same biological activity as a corresponding RAMPl protein.
- This humanized double mutant shows the same "humanized" pharmacological profile as rat K74W, showing that an additional amino acid substitution does not deleteriously effect the ability of the K74W to "humanize" the RAMPl protein.
- the present invention also includes polypeptides where two or more amino acid substitutions have been made in SEQ ID NOs:2, 4, 6, or 8, wherein the polypeptides still retain substantially the same biological activity as a corresponding RAMPl protein.
- the present invention includes embodiments where the above-described substitutions are conservative substitutions.
- polypeptides that are functional equivalents of RAMPl and have changes from the RAMPl amino acid sequence that are small deletions or insertions of amino acids could also be produced by following the same guidelines, (i.e, minimizing the differences in amino acid sequence between RAMPl and related proteins. Small deletions or insertions are generally in the range of about 1 to 5 amino acids.
- the effect of such small deletions or insertions on the biological activity of the modified RAMPl polypeptide can easily be assayed by producing the polypeptide synthetically or by making the required changes in DNA encoding RAMPl and then expressing the DNA recombinantly and assaying the protein produced by such recombinant expression. For instance, as long as amino acid residue 74 remains in a "humanized” form (i.e., Trp), then minor modifications to the remainder of the RAMPl sequence may be generated and are in turn easily tested alongside an expressed CRLR receptor to determine if the expected human pharmacological profile remains.
- the present invention also includes truncated forms of RAMPl. Such truncated proteins are useful in various assays described herein, for crystallization studies, and for structure-activity-relationship studies.
- the present invention also relates to isolated nucleic acid molecules which are fusion constructions expressing fusion proteins useful in assays to identify compounds which modulate wild-type RAMPl activity, as well as generating antibodies against RAMPl.
- isolated nucleic acid molecules which are fusion constructions expressing fusion proteins useful in assays to identify compounds which modulate wild-type RAMPl activity, as well as generating antibodies against RAMPl.
- One aspect of this portion of the invention includes, but is not limited to, glutathione S-transferase (GST)-RAMPl fusion constructs.
- Recombinant GST-RAMP1 fusion proteins may be expressed in various expression systems, including Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (pAcG2T, Pharmingen).
- Sf21 Spodoptera frugiperda
- pAcG2T baculovirus expression vector
- RAMPl fusion constructs linked to various markers including but not limited to GFP (Green fluorescent protein), the MYC epitope, His-tag, and GST.
- GFP Green fluorescent protein
- the MYC epitope the MYC epitope
- His-tag His-tag
- GST GST
- Any of a variety of procedures may be used to clone and generate a vertebrate or mammalian RAMPl, such as rat, mouse, human, etc., RAMPl.
- These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman, et al., 1988, Proc. Natl. Acad. Sci. USA 85: 8998-9002). 5' and/or 3' RACE may be performed to generate a full-length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of RAMPl cDNA.
- These gene-specific primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the RAMPl cDNA following the construction of a RAMPl -containing cDNA library in an appropriate expression vector system; (3) screening a RAMP1- containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the RAMPl protein; (4) screening a RAMPl -containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the RAMPl protein.
- EST expressed sequence tag
- This partial cDNA is obtained by the specific PCR amplification of RAMPl DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other proteins which are related to the RAMPl protein; (5) screening a RAMPl -containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA or oligonucleotide with homology to a RAMPl protein.
- This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of RAMPl cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using any of the disclosed mammalian RAMPl sequences as a template so that either the full-length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full-length version of the nucleotide sequence encoding RAMPl.
- libraries as well as libraries constructed from other cell types-or species types, may be useful for isolating a RAMPl -encoding DNA or a RAMPl homologue.
- Other types of libraries include, but are not limited to, cDNA libraries derived from other brown dog tick cell types.
- suitable cDNA libraries may be prepared from cells or cell lines which have RAMPl activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding RAMPl may be done by first measuring cell-associated RAMPl activity using any known assay available for such a purpose.
- cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Complementary DNA libraries may also be obtained from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. and Stratagene.
- This invention also includes vectors containing a humanized RAMPl gene, host cells containing the vectors, and methods of making substantially pure humanized RAMPl protein comprising the steps of introducing the humanized RAMPl gene into a host cell, and cultivating the host cell under appropriate conditions such that humanized RAMPl is produced.
- the humanized RAMPl so produced may be harvested from the host cells in conventional ways. Therefore, the present invention also relates to methods of expressing the humanized RAMPl protein and biological equivalents disclosed herein, assays employing these gene products, recombinant host cells which comprise DNA constructs which express these proteins, and compounds identified through these assays which act as agonists or antagonists of humanized RAMPl activity.
- the cloned humanized RAMPl cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector (such as pcDNA3.neo, pcDNA3.1, pCR2.1, pBlueBacHis2, pLITMUS28, the pIRES series from Clontech, as well as other examples, listed infra) containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant humanized RAMPl.
- Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their mRNAs in an appropriate host.
- Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, blue green algae, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria- yeast or bacteria-animal cells.
- An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters.
- a promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis.
- a strong promoter is one which causes mRNAs to be initiated at high frequency.
- cDNA molecules including but not limited to the following can be constructed: a cDNA fragment containing the full-length open reading frame for humanized RAMPl as well as various constructs containing portions of the cDNA encoding only specific domains of the protein or rearranged domains of the protein. All constructs can be designed to contain none, all or portions of the 5' and/or 3' untranslated region of a humanized RAMPl cDNA. The expression levels and activity of RAMPl can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells.
- this humanized RAMPl cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, bacteria, and yeast cells. Techniques for such manipulations can be found described in Sambrook, et al., supra, are well known and available to the artisan of ordinary skill in the art. Therefore, another aspect of the present invention includes host cells that have been engineered to contain and or express DNA sequences encoding the humanized RAMPl.
- An expression vector containing DNA encoding a humanized RAMPl-like protein may be used for expression of humanized RAMPl in a recombinant host cell.
- a recombinant host cell can be cultured under suitable conditions to produce humanized RAMPl or a biologically equivalent form.
- Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses.
- mammalian expression vectors which may be suitable for recombinant humanized RAMPl expression, include but are not limited to, pcDNA3.neo (Invitrogen), pcDNA3.1 (Invitrogen), pCI-neo (Promega), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Bioloabs), pcDNAI, pcDNAIamp (Invitrogen), pcDNA3 (Invitrogen), pMClneo (Stratagene), pXTl (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-l(8-2) (ATCC 37110), pdBPV- MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr
- bacterial expression vectors may be used to express recombinant humanized RAMPl in bacterial cells.
- Commercially available bacterial expression vectors which may be suitable for recombinant humanized RAMPl expression include, but are not limited to pCR2.1 (Invitrogen), pETlla (Novagen), lambda gtll (Invitrogen), and pKK223-3 (Pharmacia).
- bacterial expression vectors which may be suitable for recombinant humanized RAMPl expression include, but are not limited to pCR2.1 (Invitrogen), pETlla (Novagen), lambda gtll (Invitrogen), and pKK223-3 (Pharmacia).
- fungal cell expression vectors may be used to express recombinant RAMPl in fungal cells.
- fungal cell expression vectors which may be suitable for recombinant humanized RAMPl expression include but are not limited to pYES2 (Invitrogen) and Pichia expression vector (Invitrogen). Also, a variety of insect cell expression vectors may be used to express recombinant protein in insect cells. Commercially available insect cell expression vectors which may be suitable for recombinant expression of humanized RAMPl include but are not limited to pBlueBacIII and pBlueBacHis2 (Invitrogen), and pAcG2T (Pharmingen).
- Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as E. coli, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of bovine, porcine, monkey and rodent origin; and insect cells.
- bacteria such as E. coli
- fungal cells such as yeast
- mammalian cells including, but not limited to, cell lines of bovine, porcine, monkey and rodent origin
- insect cells For instance, one insect expression system utilizes Spodoptera frugiperda (Sf21) insect cells (Invitrogen) in tandem with a baculovirus expression vector (pAcG2T, Pharmingen).
- mammalian cells which may be suitable and which are commercially available, include but are not limited to, L cells L-M(TK') (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), Saos-2 (ATCC HTB-85), HEK 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171) CPAE (ATCC CCL 209), and 293 EBNA cells (Invitrogen).
- L cells L-M(TK') ATCC CCL 1.3
- L cells L-M ATCC CCL 1.2
- Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.
- humanized RAMPl protein may be recovered to provide humanized RAMPl protein in active form.
- humanized RAMPl protein purification procedures are available and suitable for use.
- Recombinant humanized RAMPl protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography, hydrophobic interaction chromatography, as well as metal chelate chromotography (e.g., for His-tagged proteins).
- recombinant humanized RAMPl protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length humanized RAMPl protein, or polypeptide fragments of humanized RAMPl protein.
- Expression of humanized RAMPl DNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.
- humanized RAMPl protein may be recovered to provide humanized RAMPl protein in active form.
- humanized RAMPl protein purification procedures are available and suitable for use.
- Recombinant humanized RAMPl protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography, and metal chelate chromatography.
- recombinant humanized RAMPl protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length humanized RAMPl protein, or polypeptide fragments of humanized RAMPl protein.
- the humanized RAMPl proteins of the present invention may be generated by techniques known in the art, as shown in Example Sections 1 and 2, for use in an assay procedure with the CRLR GPCR to identify CGRP receptor modulators (e.g., antagonists of CGRP receptor activity.
- an assay procedure to identify such receptor modulators will contain a humanized CGRP receptor of the present invention, and a test compound or sample which contains a putative CGRP receptor modulator.
- the test compounds or samples may be tested directly on, for example, purified receptor protein whether native or recombinant, subcellular fractions of receptor-producing cells whether native or recombinant, and/or whole cells expressing the receptor whether native or recombinant.
- the test compound or sample may be added to the receptor in the presence or absence of a known labeled or unlabelled receptor ligand.
- a known labeled or unlabelled receptor ligand For instance, recombinant membrane fractions containing a humanized CRGP receptor can be used to screen for compounds which inhibit binding of 125 I-CGRP to the receptor in a radioligand biding assay.
- the modulating activity of the test compound or sample may be determined by, for example, analyzing the ability of the test compound or sample to bind to the receptor, activate the receptor, inhibit receptor activity, inhibit or enhance the binding of other compounds to the receptor, modify receptor regulation, or modify an intracellular activity.
- the present invention is also directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding a humanized CGRP receptor as well as the function of a humanized CGRP receptor in vivo.
- Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules.
- Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding CRLR and/or humanized RAMPl receptor respectively, or the function either protein.
- Compounds that modulate the expression of DNA or RNA encoding the CGRP receptor or the function of this receptor may be detected by a variety of assays.
- the assay may be a simple "yes/no" assay to determine whether there is a change in expression or function.
- the assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample.
- Marmoset and Cynomolgous RAMPl cDNA Cloning A partial marmoset RAMPl cDNA and cynomolgous cDNA were isolated from frontal brain cDNA using the polymerase chain reaction (PCR).
- the PCR primers were based upon human RAMPl (5'-CTGCCAGGAGGCTAACTACG-3' [SEQ ID NO:25] and 5'-CACGATGAAGGGGTAGAGGA-3' [SEQ ID NO:26]).
- Amplification reactions consisted of 40 cycles of 45 sec at 94°C, 45 sec at 58°C, and 1 min at 72°C and were carried out according to the manufacturer's recommended protocol for PLATINUM Taq PCR DNA polymerase (Invitrogen). Multiple subclones were sequenced to rule out potential errors.
- Table 3 shows various wild type mammalian RAMPl nucleotide and amino acid sequences.
- Figure 4 also shows an alignment of amino acid sequences through the "humanizing residue” at residue #74, including human and marmoset (Trp), rat and mouse (Lys, which may be mutagenized to Trp) and pig (Arg, which may be mutaginized to Trp).
- Figure 1 shows the alignment of the full length amino acid sequences for human, rat and mouse RAMPl.
- Chimera 1 was created by replacing the nucleotides coding for the first 66 amino acids of rRAMPl with the corresponding nucleotides of hRAMPl by using the Bsgl restriction site along with a Nhel site located in the cloning vector.
- Chimera 2 was created by replacing the nucleotides coding for the first 112 amino acids of rRAMPl with the corresponding nucleotides of hRAMPl by using the SanDI restriction site along with a Nhel site located in the cloning vector.
- Rat RAMPl site-directed mutagenesis was performed by using the Quick Change Site-directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. Lysine at position 74 of rRAMPl was replaced with the corresponding human/marmoset amino acid tryptophan utilizing two complementary mutant oligonucleotide primers
- EBNA cells were cultured in DMEM with 4.5 g/L glucose, 1 mM sodium pyruvate and 2 mM glutamine supplemented with 10% Fetal Bovine Serum (FBS), 100 units/mL penicillin and 100 ⁇ g/mL streptomycin, and maintained at 37°C and 95% humidity. Cells were subcultured by treatment with 0.25% trypsin with 0.1% EDTA in HBSS.
- FBS Fetal Bovine Serum
- the cells were seeded at 2.0 xl0 7 /dish in 500 cm 2 dishes. The following day, the cells were re-fed with fresh growth medium 1 hour before transfection. Transfections were performed by combining 60 ⁇ g/dish DNA with 180 ⁇ g/dish Lipofectamine 2000 (Life Technologies). cDNA's for CRLR and RAMPl in the mammalian expression vector pcDNA3.1 were co-transfected in equal amounts. The transfection cocktail was added directly to the medium and this mixture was replaced with fresh medium 24 hours later. The cells were harvested for membranes 48 hours post-transfection.
- binding assays 1.5-25 ⁇ g of membranes (dependent upon receptor expression levels) were incubated for 3 hours at room temperature in binding buffer (10 mM HEPES, 5 mM MgCl 2 , 0.2% BSA) containing 10 pM 125 I-hCGRP
- the small molecule antagonists Compound 1 and BIBN4096BS had lower affinity for rCRLR rRAMPl than for the transfected human CGRP receptor (Table 4; see Figure 2 for structure of BD3N4096BS and Compounds 1 and 2).
- the peptide antagonist CGRP 8 . 37 displayed similar affinities for CGRP receptors from human and rat, with IC 50 values of 2.8 and 2.0 nM, respectively.
- IC 50 values 2.8 and 2.0 nM
- RAMPs are accessory proteins predicted to contain a large extracellular N-terminal domain and a single transmembrane (TM) spanning domain.
- TM transmembrane
- Compound 1 exhibited >10-fold higher affinity for the rCRLR/rK74W RAMPl receptor than for the native human receptor, perhaps due to favorable interactions between the dibromotyrosyl moiety and the tryptophan in the RAMPl mutant. These results suggested that the affinities of these small molecule antagonists for the CGRP receptor were heavily influenced by the nature of amino acid 74 of RAMPl.
- RAMPs One of the demonstrated functions of RAMPs is to ensure proper cell surface targeting of CRLR.
- the functional significance of glycosylation was therefore addressed because the glycosylation state of the rat CGRP receptor had not been characterized previously; furthermore, the possibility existed that rat and human RAMPl resulted in differential glycosylation of CRLR and that this effect determined the observed differences in antagonist affinities.
- Using an antibody to rCRLR and deglycosylation enzymes the glycosylation state of rCRLR associated with rat or human RAMPl was determined.
- the membranes from the competitive binding experiments were treated with Peptide-N-Glycosidase F (PNGase F) and Endoglycosidase Fl (Endo Fl).
- PNGase F catalyzes the hydrolysis of mature glycoproteins
- Endo Fl cleaves N-linked high mannose and hybrid oligosaccharides, but not complex oligosaccharides.
- PNGase F Peptide-N-Glycosidase F
- Endo Fl Endoglycosidase Fl
- EXAMPLE 2 A mouse cDNA for CRLR was isolated from mouse brain cDNA using the polymerase chain reaction (PCR). PCR primers
- PCR primers (5'-ATGCGGCCGCGTGGGGCTCTGCTTGCCATG-3' [SEQ ID NO:31] and 5'-CGGGATCCCTCATCACCTGGGATACCTAC-3' [SEQ ID NO:32]) were based upon the published mouse RAMPl sequence (Knut, et al., 2000, Mol. Cell. Endocrinol. 162: 35-43). Engineered 5'NotI and 3'BamHI sites were utilized for subcloning into the expression vector pcDNA3.1/Hygro(-) (Invitrogen). Mouse RAMPl site-directed mutagenesis was performed by the same method employed in EXAMPLE 1.
- the mouse RAMPl expression vector construct was used as template utilizing two complementary mutant oligonucleotide primers (5'-GCTCACTTACTGCACCTGGCACGTGGCGCACACG [SEQ ID NO:33] and 5'-CGTGTGCGCCACGTGCCAGGTGCAGTAAGTGAGC [SEQ ID NO:34]). This mutation was accomplished by substituting a TG at positions 1 and 2 of the mouse lysine codon (AAG) resulting in the tryptophan codon TGG (mK74W RAMPl). Cell culture, DNA transfection, membrane preparation, and radioligand biding studies were carried out as in EXAMPLE 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32529501P | 2001-09-27 | 2001-09-27 | |
US325295P | 2001-09-27 | ||
PCT/US2002/030501 WO2003027252A2 (en) | 2001-09-27 | 2002-09-26 | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1438325A2 true EP1438325A2 (en) | 2004-07-21 |
EP1438325A4 EP1438325A4 (en) | 2005-02-23 |
EP1438325B1 EP1438325B1 (en) | 2009-12-30 |
Family
ID=23267273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02763731A Expired - Lifetime EP1438325B1 (en) | 2001-09-27 | 2002-09-26 | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
Country Status (7)
Country | Link |
---|---|
US (1) | US7193070B2 (en) |
EP (1) | EP1438325B1 (en) |
JP (1) | JP4603261B2 (en) |
AT (1) | ATE453661T1 (en) |
CA (1) | CA2461917C (en) |
DE (1) | DE60234944D1 (en) |
WO (1) | WO2003027252A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2371861B1 (en) | 2002-01-25 | 2017-08-09 | Novo Nordisk A/S | Monoclonal antibodies against extracellular loops of C5aR |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
MXPA04011960A (en) | 2002-06-05 | 2005-03-31 | Squibb Bristol Myers Co | Calcitonin gene related peptide receptor antagonists. |
WO2004097421A2 (en) * | 2003-04-29 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl) |
AR046787A1 (en) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | HETEROCICLIC ANTIMIGRAN AGENTS |
CN100558428C (en) | 2003-12-05 | 2009-11-11 | 布里斯托尔-迈尔斯·斯奎布公司 | Calcitonin gene related peptide receptor antagonists |
WO2005060739A1 (en) * | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
US7384931B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
FR2882628B1 (en) * | 2005-03-04 | 2011-03-18 | Centre Nat Rech Scient | TRANSGENIC MICE AND THEIR APPLICATIONS AS AN EXPERIMENTAL MODEL |
US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
ES2664854T3 (en) | 2005-11-14 | 2018-04-23 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against a peptide related to the calcitonin gene to treat cluster headache |
JP2009201355A (en) * | 2006-06-02 | 2009-09-10 | Osaka Univ | Nonhuman model animal of hypertension |
RU2009110154A (en) | 2006-08-22 | 2010-09-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ANTIBODIES AGAINST C5aR WITH IMPROVED PROPERTIES |
US20100093018A1 (en) * | 2007-04-26 | 2010-04-15 | Achillion Pharmaceuticals, Inc. | Cells expressing chimeric proteins and assays using such cells |
WO2009103113A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES |
CN101959528A (en) | 2008-03-04 | 2011-01-26 | 辉瑞有限公司 | Methods of treating chronic pain |
JO3382B1 (en) * | 2008-12-23 | 2019-03-13 | Amgen Inc | Human cgrp receptor binding antibodies |
CA2771186C (en) | 2009-08-28 | 2018-01-02 | Rinat Neuroscience Corporation | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
PT3424953T (en) | 2011-06-06 | 2020-11-03 | Novo Nordisk As | Therapeutic antibodies |
JP6267986B2 (en) * | 2014-02-13 | 2018-01-24 | 株式会社特殊免疫研究所 | In vivo evaluation method for molecular target substances that bind to specific human molecules |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
SI3119431T1 (en) | 2014-03-21 | 2024-06-28 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
MX2017003247A (en) | 2014-09-15 | 2017-11-30 | Amgen Inc | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof. |
JOP20200116A1 (en) | 2015-04-24 | 2017-06-16 | Amgen Inc | Methods for treating or preventing migraine headache |
CN109952314A (en) | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | Treat intractable migraine |
CN111954678A (en) | 2018-04-02 | 2020-11-17 | 美国安进公司 | Errenitumumab composition and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4882609A (en) * | 1984-11-19 | 1989-11-21 | Max-Planck Gesellschaft Zur Forderung Der Wissenschafter E.V. | Semiconductor devices with at least one monoatomic layer of doping atoms |
US4908678A (en) * | 1986-10-08 | 1990-03-13 | Semiconductor Energy Laboratory Co., Ltd. | FET with a super lattice channel |
US5081513A (en) * | 1991-02-28 | 1992-01-14 | Xerox Corporation | Electronic device with recovery layer proximate to active layer |
US5606177A (en) * | 1993-10-29 | 1997-02-25 | Texas Instruments Incorporated | Silicon oxide resonant tunneling diode structure |
US6255150B1 (en) * | 1997-10-23 | 2001-07-03 | Texas Instruments Incorporated | Use of crystalline SiOx barriers for Si-based resonant tunneling diodes |
-
2002
- 2002-09-26 WO PCT/US2002/030501 patent/WO2003027252A2/en active Application Filing
- 2002-09-26 JP JP2003530824A patent/JP4603261B2/en not_active Expired - Fee Related
- 2002-09-26 AT AT02763731T patent/ATE453661T1/en not_active IP Right Cessation
- 2002-09-26 EP EP02763731A patent/EP1438325B1/en not_active Expired - Lifetime
- 2002-09-26 CA CA2461917A patent/CA2461917C/en not_active Expired - Fee Related
- 2002-09-26 DE DE60234944T patent/DE60234944D1/en not_active Expired - Lifetime
- 2002-09-26 US US10/490,594 patent/US7193070B2/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
DOODS H ET AL: "PHARMACOLOGICAL PROFILE OF BIBN4096BS, THE FIRST SELECTIVE SMALL MOLECULE CGRP ANTAGONIST" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 129, no. 3, 2000, pages 420-423, XP000992559 ISSN: 0007-1188 * |
MALLEE J J ET AL: "Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 16, 19 April 2002 (2002-04-19), pages 14294-14298, XP002271313 ISSN: 0021-9258 * |
See also references of WO03027252A2 * |
Also Published As
Publication number | Publication date |
---|---|
US7193070B2 (en) | 2007-03-20 |
US20040197859A1 (en) | 2004-10-07 |
JP4603261B2 (en) | 2010-12-22 |
EP1438325A4 (en) | 2005-02-23 |
ATE453661T1 (en) | 2010-01-15 |
CA2461917A1 (en) | 2003-04-03 |
WO2003027252A2 (en) | 2003-04-03 |
JP2005503809A (en) | 2005-02-10 |
DE60234944D1 (en) | 2010-02-11 |
CA2461917C (en) | 2012-01-17 |
WO2003027252A3 (en) | 2003-06-19 |
EP1438325B1 (en) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2461917C (en) | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods | |
KR102699643B1 (en) | Humanized T cell-mediated immune responses in nonhuman animals | |
US20030166239A1 (en) | Mammalian osteoregulins | |
EP1241933B1 (en) | Melanocortin-3 receptor deficient cells, transgenic mice and methods of selecting compounds which regulate body weight | |
JPWO2012029958A1 (en) | Screening method for anti-diabetic drugs using newly identified insulin secretion regulator | |
US20040053812A1 (en) | Methods | |
US20040093627A1 (en) | Methods | |
WO2001048483A2 (en) | Method for screening of appetite control agents | |
US20040093626A1 (en) | Methods | |
JP2003525596A (en) | Melanocortin-4 receptor deficient cells, non-human transgenic animals, and method for selecting weight-regulating compounds | |
JP2002360120A (en) | P1-3 KINASE p85 SUBUNIT-CONTAINING TRANSGENIC ANIMAL OF DOMINANT NEGATIVE MUTANT FORM | |
US7321074B1 (en) | Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight | |
WO2001025425A1 (en) | NUCLEAR LOCALIZED RecQ5 TYPE DNA HELICASE | |
US20050250720A1 (en) | Novel compound | |
US20020099190A1 (en) | Estrogen-regulated unconventional myosin-related protein: compositions and methods of use | |
KR20240132525A (en) | Humanized t cell mediated immune responses in non-human animals | |
EP1279332A2 (en) | Transgenic non-human mammal | |
JP2008031043A (en) | Chicken lif (leukemia inhibitory factor) protein and its use | |
JP2003116407A (en) | Radixin knock-out animal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040427 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050112 |
|
17Q | First examination report despatched |
Effective date: 20060505 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SERVOPATENT GMBH |
|
REF | Corresponds to: |
Ref document number: 60234944 Country of ref document: DE Date of ref document: 20100211 Kind code of ref document: P |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: MERCK SHARP & DOHME CORP. |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20091230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100330 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100410 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100331 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20101001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100926 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20110729 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFUS Owner name: SCHERING CORPORATION, US Free format text: FORMER OWNER: MERCK SHARP + DOHME CORP., US Ref country code: CH Ref legal event code: PFA Owner name: MERCK SHARP & DOHME CORP. Free format text: SCHERING CORPORATION#2000 GALLOPING HILL ROAD#KENILWORTH, NJ 07033 (US) -TRANSFER TO- MERCK SHARP & DOHME CORP.#126 EAST LINCOLN AVENUE#RAHWAY, NEW JERSEY 07065 (US) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100926 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091230 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Owner name: SCHERING CORPORATION, US Effective date: 20130318 Ref country code: FR Ref legal event code: CD Owner name: SCHERING CORPORATION, US Effective date: 20130319 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20130704 AND 20130710 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 60234944 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., US Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US Effective date: 20130625 Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 60234944 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., US Free format text: FORMER OWNER: MERCK & CO., INC., WHITEHOUSE STATION, US Effective date: 20130618 Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE Effective date: 20130625 Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER, DE Effective date: 20130618 Ref country code: DE Ref legal event code: R081 Ref document number: 60234944 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., US Free format text: FORMER OWNER: SCHERING CORPORATION, RAHWAY, US Effective date: 20130626 Ref country code: DE Ref legal event code: R081 Ref document number: 60234944 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNER: MERCK & CO., INC., WHITEHOUSE STATION, N.J., US Effective date: 20130618 Ref country code: DE Ref legal event code: R081 Ref document number: 60234944 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, NEW JERSEY, US Effective date: 20130625 Ref country code: DE Ref legal event code: R081 Ref document number: 60234944 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNER: SCHERING CORPORATION, RAHWAY, US Effective date: 20130626 Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE Effective date: 20130618 Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE Effective date: 20130626 Ref country code: DE Ref legal event code: R082 Ref document number: 60234944 Country of ref document: DE Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE Effective date: 20130625 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20130826 Year of fee payment: 12 Ref country code: GB Payment date: 20130827 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20130930 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130930 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60234944 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20140926 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150529 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150401 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140926 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140930 |